Emily Benfield
Family · Roan Mountain, TNNPI 1710438486
Payments from drug & device makers
Across 294 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$765
- AstraZeneca$723
- AbbVie$618
- Lilly USA, LLC$435
- GSK$338
- Bayer$295
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,198100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $765 |
| AstraZeneca | 38 | $723 |
| AbbVie | 52 | $618 |
| Lilly USA, LLC | 31 | $435 |
| GSK | 24 | $338 |
| Bayer | 17 | $295 |
| Pfizer | 12 | $183 |
| Boehringer Ingelheim | 9 | $156 |
| Amarin Pharma, Inc. | 5 | $79 |
| Mylan Specialty L.p. | 5 | $73 |
| Johnson & Johnson | 4 | $62 |
| Merck | 4 | $61 |
| Novartis | 3 | $60 |
| Exact Sciences | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Lundbeck LLC | 1 | $25 |
| Biogen | 1 | $25 |
| Insulet Corporation | 1 | $19 |
| Viatris Specialty LLC | 1 | $16 |
How this compares
$4,198 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 69 | $104,277 |
| OzempicSemaglutide | 84 | $90,105 |
| FarxigaDapagliflozin Propanediol | 80 | $82,568 |
| JardianceEmpagliflozin | 49 | $71,581 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $47,560 |
| KerendiaFinerenone | 32 | $42,533 |
| EliquisApixaban | 42 | $32,553 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,999 |
| JanuviaSitagliptin Phosphate | 18 | $15,934 |
| TrulicityDulaglutide | 14 | $13,854 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,878 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $8,730 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,879 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $6,290 |
| XareltoRivaroxaban | 11 | $6,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $765 | $194,382153 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $723 | $134,130166 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Trijardy Xr | $156 | $84,75074 claims |
| BayerKerendia | $295 | $42,53332 claims |
| PfizerEliquis | $183 | $32,55342 claims |
| GSKTrelegy Ellipta | $338 | $24,99935 claims |
| MerckJanuvia | $61 | $15,93418 claims |
| Lilly USA, LLCTrulicity | $435 | $13,85414 claims |
| Johnson & JohnsonXarelto | $62 | $6,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.
Other family in Roan Mountain
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.